サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1594923

微生物発酵技術の世界市場

Microbial Fermentation Technology

出版日
ページ情報
英文 324 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
微生物発酵技術の世界市場
出版日: 2024年11月22日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 324 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

微生物発酵技術の世界市場は2030年までに452億米ドルに到達

2023年に315億米ドルと推定される微生物発酵技術の世界市場は、2023年から2030年にかけてCAGR 5.3%で成長し、2030年には452億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである抗生物質用途は、CAGR7.5%を記録し、分析期間終了時には162億米ドルに達すると予測されます。酵素応用分野の成長率は、分析期間中CAGR 3.4％と推定されます。

米国市場は85億米ドルと推定、中国はCAGR 9.2％で成長すると予測

米国の微生物発酵技術市場は2023年に85億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに102億米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは9.2%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.5%と4.4%と予測されています。欧州では、ドイツがCAGR 3.4%で成長すると予測されています。

世界の微生物発酵技術市場- 主要動向と促進要因まとめ

微生物発酵技術とは何か、なぜ現代のバイオテクノロジーにおいて重要なのか？

微生物発酵技術は、バクテリア、酵母、菌類などの微生物を使って、発酵により原材料を価値ある製品に変換する生物学的プロセスです。この技術は、制御された条件下で微生物の代謝活性を利用し、医薬品、酵素、バイオ燃料、アミノ酸、有機酸、抗生物質、プロバイオティクスなど、さまざまな生物製品を生産します。発酵は、バッチ発酵、連続発酵、供給バッチ発酵など様々な形態で行われ、それぞれ異なる生産規模や製品タイプに適しています。

微生物発酵技術の重要性は、化学的合成が困難な、高価値で持続可能な、しばしば複雑な生体分子を生産する能力にあります。インスリンやワクチンからバイオ燃料や食品添加物まで、あらゆるもの生産を可能にし、現代のバイオテクノロジー、医薬品、飲食品産業、農業の要となっています。持続可能な生産方法に対する世界の需要が高まる中、微生物発酵は、多様な産業にわたって不可欠な製品を生産するための、より環境に優しく効率的な代替手段を提供しています。

技術の進歩はどのように微生物発酵技術市場を形成しているか？

技術の進歩は、微生物発酵技術の効率性、拡張性、汎用性を大幅に向上させ、様々な用途におけるイノベーションを促進しています。主要な発展の一つは、遺伝子工学と合成生物学の台頭です。微生物の遺伝子経路を改変することで、研究者は医薬品、酵素、バイオ燃料、その他の生体分子の生産量を増やすことができます。また、このような操作された菌株は、以前は達成できなかった新規化合物を生産することも可能であり、創薬や産業バイオテクノロジーにおける微生物発酵の応用の可能性を広げています。

先進的なバイオリアクターの開発により、微生物発酵の能力はさらに向上しました。最新のバイオリアクターは、温度、pH、酸素レベル、栄養供給などのパラメーターを調整する自動制御システムを備えており、微生物の最適な増殖条件を保証しています。連続フロー・バイオリアクターや無細胞システムのような技術革新は、生産効率を高め、ダウンタイムを削減し、より高い生産性とスケーラビリティを達成することを可能にしています。これらのバイオリアクターは、さまざまな微生物培養に適合させることができるため、幅広い生体分子の柔軟な生産が可能になります。

メタボロミクス、ゲノミクス、バイオインフォマティクスの進歩も、微生物発酵技術を形成しています。代謝工学技術は、微生物の代謝経路を微調整し、基質から目的生成物への変換効率を高めることを可能にします。ゲノミクスとバイオインフォマティクスは、微生物のDNAに関する洞察を提供し、生合成を担う遺伝子クラスターの同定を可能にします。これは菌株の改良、より迅速なプロセスの最適化、新しい発酵ベースの製品の開発に役立ちます。さらに、CRISPR-Cas9遺伝子編集技術は、特定の発酵プロセスに合わせたカスタム株の作成を加速し、製品の収率を向上させ、生産コストを削減しました。こうした技術革新は、微生物発酵の能力を拡大するだけでなく、精密バイオテクノロジー、持続可能な製造、さまざまな産業における効率的な生産といった、より広範な動向にも合致しています。

さまざまな分野での微生物発酵技術の新たな応用例とは？

微生物発酵技術は、複雑な生体分子を持続的に生産する必要性から、幅広い分野で応用が広がっています。製薬業界では、抗生物質、ワクチン、インスリン、その他の治療用タンパク質の生産に微生物発酵が使用されています。微生物発酵は、糖尿病、がん、自己免疫疾患などの治療に不可欠な生物製剤やバイオシミラーの大量生産を支えています。発酵に基づく医薬品の生産は、高い純度、一貫性、拡張性を保証するため、多くの製薬会社に好まれる方法となっています。

飲食品業界では、微生物発酵はアミノ酸、有機酸（クエン酸や乳酸など）、ビタミン、プロバイオティクスなどの食品成分の生産に広く利用されています。これらの生物生産物は、食品の栄養価、風味、保存性を高める。発酵はまた、ヨーグルト、チーズ、ビール、コンブチャのような発酵食品の製造の鍵でもあり、健康的で機能的な食品に対する需要の高まりを支えています。さらに、植物由来の代替食肉に発酵を利用することで、動物性食品に酷似したタンパク質、風味、食感を作り出す方法が提供されるため、持続可能な食生活の台頭を支えるものとして支持を集めています。

バイオ燃料産業では、トウモロコシ、サトウキビ、農業残渣などの再生可能なバイオマス資源からバイオエタノール、バイオブタノール、その他のバイオ燃料を生産するために微生物発酵が用いられています。このプロセスは、化石燃料に代わる持続可能な代替燃料を提供し、温室効果ガスの排出を削減し、エネルギーの自立を支援します。農業分野では、発酵技術が生物農薬、生物肥料、飼料添加物の生産に採用され、化学物質の投入による環境への影響を低減しながら、作物の収量と家畜の健康を向上させています。これらの部門における微生物発酵の用途の拡大は、工業製品と消費者製品の両方において、持続可能で効率的かつスケーラブルな生産プロセスを可能にする上で、その重要な役割を浮き彫りにしています。

微生物発酵技術市場の成長の原動力は？

微生物発酵技術市場の成長は、持続可能な生産方法に対する需要の増加、ヘルスケアにおける生物製剤の普及率の上昇、遺伝子工学の進歩など、いくつかの要因によってもたらされます。主な成長要因のひとつは、産業界全体で持続可能な生産が世界的に推進されていることです。企業や政府がカーボンフットプリントの削減を目指す中、微生物発酵は従来の化学合成や石油化学ベースのプロセスに代わる、より環境に優しい選択肢を提供します。再生可能な原料から高価値の生体分子を生産する能力は、循環経済モデルに合致し、食品、農業、エネルギーなどの分野における持続可能性の目標をサポートします。

ヘルスケア分野における生物製剤とバイオシミラーの使用拡大が、微生物発酵技術の需要をさらに促進しています。ワクチン、モノクローナル抗体、治療用タンパク質を含む生物製剤は、その構造が複雑なため、主に微生物発酵によって生産されます。世界中のヘルスケアシステムが慢性疾患の治療のために生物製剤への依存度を高めるにつれて、効率的でスケーラブルな発酵プロセスに対する需要が急増しています。さらに、バイオシミラーに対する政府の支援と規制当局の承認が、発酵ベースの製造施設への投資を促進し、市場の成長を後押ししています。

合成生物学と遺伝子工学の進歩も微生物発酵市場の拡大に寄与しています。より高い収量、より迅速な生産、新規の製品合成のための微生物工学の能力は、発酵ベースの生産に新たな道を開いた。これにより、バイオベースのプラスチック、特殊化学品、栄養補助食品のような革新的な製品が開発されるようになった。さらに、イノミクス技術（ゲノミクス、プロテオミクス、メタボロミクス）の進歩により、菌株開発と発酵の最適化が改善され、微生物発酵のコスト効率と効率が向上しています。

バイオプロセス工学、合成生物学、持続可能な製造方法における技術革新が進行しており、微生物発酵技術市場は力強い成長を遂げようとしています。これらの動向は、再生可能で高価値かつスケーラブルなバイオ製品への需要の高まりと相まって、微生物発酵を、様々な分野における持続可能性、効率性、世界の健康に焦点を当てた現代のバイオテクノロジー戦略にとって不可欠な要素にしています。

セグメント

用途（抗生物質、酵素、組み換えタンパク質、モノクローナル抗体、低分子化合物、ワクチン、その他の用途）、最終用途（研究開発・製造受託機関（CDMO）、バイオ製薬会社、研究開発受託機関（CRO）、学術・研究機関）

調査対象企業の例（注目の44社）

  • Amyris, Inc.
  • Biocon Ltd.
  • BioVectra Inc.
  • Danone UK
  • F. Hoffmann-La Roche AG
  • Koninklijke DSM NV
  • Lonza Group AG
  • Novozymes A/S
  • TerraVia Holdings, Inc.
  • United Breweries Ltd.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP16588

Global Microbial Fermentation Technology Market to Reach US$45.2 Billion by 2030

The global market for Microbial Fermentation Technology estimated at US$31.5 Billion in the year 2023, is expected to reach US$45.2 Billion by 2030, growing at a CAGR of 5.3% over the analysis period 2023-2030. Antibiotics Application, one of the segments analyzed in the report, is expected to record a 7.5% CAGR and reach US$16.2 Billion by the end of the analysis period. Growth in the Enzymes Application segment is estimated at 3.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$8.5 Billion While China is Forecast to Grow at 9.2% CAGR

The Microbial Fermentation Technology market in the U.S. is estimated at US$8.5 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$10.2 Billion by the year 2030 trailing a CAGR of 9.2% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.5% and 4.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.4% CAGR.

Global Microbial Fermentation Technology Market - Key Trends & Drivers Summarized

What Is Microbial Fermentation Technology, and Why Is It So Crucial in Modern Biotechnology?

Microbial Fermentation Technology is a biological process that uses microorganisms like bacteria, yeast, and fungi to convert raw materials into valuable products through fermentation. This technology harnesses the metabolic activities of microbes under controlled conditions to produce a wide range of bioproducts, including pharmaceuticals, enzymes, biofuels, amino acids, organic acids, antibiotics, and probiotics. Fermentation can occur in various forms, such as batch, fed-batch, or continuous fermentation, each suited to different production scales and types of products.

The importance of microbial fermentation technology lies in its ability to produce high-value, sustainable, and often complex biomolecules that are challenging to synthesize chemically. It enables the production of everything from insulin and vaccines to biofuels and food additives, making it a cornerstone of modern biotechnology, pharmaceuticals, food and beverage industries, and agriculture. As global demand for sustainable production methods increases, microbial fermentation offers a greener, more efficient alternative for producing essential products across diverse industries.

How Are Technological Advancements Shaping the Microbial Fermentation Technology Market?

Technological advancements have significantly enhanced the efficiency, scalability, and versatility of Microbial Fermentation Technology, driving innovation across various applications. One of the major developments is the rise of genetic engineering and synthetic biology, which allows for the manipulation of microbial strains to produce higher yields of desired products. By modifying the genetic pathways of microorganisms, researchers can increase the production of pharmaceuticals, enzymes, biofuels, and other biomolecules. These engineered strains can also produce novel compounds that were previously unattainable, expanding the potential applications of microbial fermentation in drug discovery and industrial biotechnology.

The development of advanced bioreactors has further improved the capabilities of microbial fermentation. Modern bioreactors are equipped with automated control systems that regulate parameters like temperature, pH, oxygen levels, and nutrient supply, ensuring optimal growth conditions for microorganisms. Innovations like continuous-flow bioreactors and cell-free systems have enhanced production efficiency and reduced downtime, making it possible to achieve higher productivity and scalability. These bioreactors can be adapted for different microbial cultures, enabling flexible production of a wide range of biomolecules.

Advancements in metabolomics, genomics, and bioinformatics have also shaped microbial fermentation technology. Metabolic engineering techniques allow for fine-tuning the metabolic pathways of microorganisms, increasing the efficiency of substrate conversion into target products. Genomics and bioinformatics provide insights into microbial DNA, enabling the identification of gene clusters responsible for biosynthesis. This aids in strain improvement, faster process optimization, and the development of new fermentation-based products. Additionally, CRISPR-Cas9 gene-editing technology has accelerated the creation of custom strains tailored for specific fermentation processes, improving product yields and reducing production costs. These technological innovations not only expand the capabilities of microbial fermentation but also align with broader trends toward precision biotechnology, sustainable manufacturing, and efficient production in various industries.

What Are the Emerging Applications of Microbial Fermentation Technology Across Different Sectors?

Microbial Fermentation Technology is finding expanding applications across a wide range of sectors, driven by the need for sustainable production of complex biomolecules. In the pharmaceutical industry, microbial fermentation is used to produce antibiotics, vaccines, insulin, and other therapeutic proteins. It supports large-scale production of biologics and biosimilars, which are critical for treating diseases like diabetes, cancer, and autoimmune disorders. Fermentation-based production of drugs ensures high purity, consistency, and scalability, making it a preferred method for many pharmaceutical companies.

In the food and beverage industry, microbial fermentation is widely used to produce food ingredients, such as amino acids, organic acids (like citric acid and lactic acid), vitamins, and probiotics. These bioproducts enhance the nutritional value, flavor, and shelf-life of food products. Fermentation is also key to the production of fermented foods like yogurt, cheese, beer, and kombucha, supporting the growing demand for healthy and functional foods. Additionally, the use of fermentation in plant-based meat alternatives has gained traction, as it provides a way to create proteins, flavors, and textures that closely mimic animal products, supporting the rise of sustainable diets.

In the biofuel industry, microbial fermentation is used to produce bioethanol, biobutanol, and other biofuels from renewable biomass sources like corn, sugarcane, and agricultural residues. This process provides a sustainable alternative to fossil fuels, reducing greenhouse gas emissions and supporting energy independence. In the agricultural sector, fermentation technology is employed to produce biopesticides, biofertilizers, and animal feed additives, improving crop yields and livestock health while reducing the environmental impact of chemical inputs. The expanding applications of microbial fermentation across these sectors highlight its critical role in enabling sustainable, efficient, and scalable production processes in both industrial and consumer products.

What Drives Growth in the Microbial Fermentation Technology Market?

The growth in the Microbial Fermentation Technology market is driven by several factors, including increasing demand for sustainable production methods, rising prevalence of biologics in healthcare, and advancements in genetic engineering. One of the primary growth drivers is the global push for sustainable production across industries. As businesses and governments aim to reduce carbon footprints, microbial fermentation offers a greener alternative to traditional chemical synthesis and petrochemical-based processes. The ability to produce high-value biomolecules from renewable feedstocks aligns with the circular economy model, supporting sustainability goals in sectors like food, agriculture, and energy.

The growing use of biologics and biosimilars in the healthcare sector has further fueled demand for microbial fermentation technology. Biologics, which include vaccines, monoclonal antibodies, and therapeutic proteins, are primarily produced through microbial fermentation due to the complexity of their structures. As healthcare systems worldwide increase their reliance on biologics to treat chronic diseases, the demand for efficient and scalable fermentation processes has surged. Additionally, government support and regulatory approvals for biosimilars have driven investments in fermentation-based manufacturing facilities, boosting market growth.

Advancements in synthetic biology and genetic engineering have also contributed to the expansion of the microbial fermentation market. The ability to engineer microorganisms for higher yield, faster production, and novel product synthesis has opened new avenues for fermentation-based production. This has led to the development of innovative products like bio-based plastics, specialty chemicals, and nutraceuticals. Furthermore, advancements in omics technologies (genomics, proteomics, metabolomics) have improved strain development and fermentation optimization, making microbial fermentation more cost-effective and efficient.

With ongoing innovations in bioprocess engineering, synthetic biology, and sustainable manufacturing practices, the microbial fermentation technology market is poised for strong growth. These trends, combined with increasing demand for renewable, high-value, and scalable bioproducts, make microbial fermentation a vital component of modern biotechnology strategies focused on sustainability, efficiency, and global health across various sectors.

SCOPE OF STUDY:

The report analyzes the Microbial Fermentation Technology market in terms of US$ Million by the following Application; End-Use, and Geographic Regions/Countries:

Segments:

Application (Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines, Other Applications); End-Use (Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs), Academic & Research Institutes)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

  • Amyris, Inc.
  • Biocon Ltd.
  • BioVectra Inc.
  • Danone UK
  • F. Hoffmann-La Roche AG
  • Koninklijke DSM NV
  • Lonza Group AG
  • Novozymes A/S
  • TerraVia Holdings, Inc.
  • United Breweries Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Microbial Fermentation Technology - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing Demand for Bio-based Products Spurs Adoption of Microbial Fermentation
    • Rising Use of Fermentation in Pharmaceutical Production Expands Market Scope
    • Growing Applications in Food and Beverages Set the Stage for Market Expansion
    • Regulatory Push for Sustainable Production Generates Demand for Fermentation Solutions
    • Growing Focus on Probiotics and Nutraceuticals Drives Fermentation Adoption
    • Use in Waste Treatment and Bioenergy Production Expands Addressable Market
    • Increasing Demand for Amino Acids Propels Fermentation Technology Market
    • Strong Growth in Bioplastics Market Generates Demand for Fermentation Technology
    • Rising Need for Organic Fertilizers Drives Adoption of Microbial Fermentation
    • Increasing Focus on Microbial Fermentation in Agriculture Spurs Market Demand
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Microbial Fermentation Technology Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Microbial Fermentation Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Microbial Fermentation Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Microbial Fermentation Technology by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Antibiotics by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Enzymes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Enzymes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Enzymes by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Recombinant Proteins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Recombinant Proteins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Recombinant Proteins by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Monoclonal Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Monoclonal Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Monoclonal Antibodies by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Small Molecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Small Molecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Small Molecules by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Vaccines by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Contract Development & Manufacturing Organizations (CDMOs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Contract Development & Manufacturing Organizations (CDMOs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Contract Development & Manufacturing Organizations (CDMOs) by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Biopharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Biopharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: World 16-Year Perspective for Biopharmaceutical Companies by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Contract Research Organizations (CROs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Contract Research Organizations (CROs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: World 16-Year Perspective for Contract Research Organizations (CROs) by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Academic & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Academic & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: World 16-Year Perspective for Academic & Research Institutes by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Microbial Fermentation Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 38: USA Recent Past, Current & Future Analysis for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Microbial Fermentation Technology by Application - Percentage Breakdown of Value Revenues for Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Microbial Fermentation Technology by End-Use - Percentage Breakdown of Value Revenues for Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Microbial Fermentation Technology by Application - Percentage Breakdown of Value Revenues for Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Microbial Fermentation Technology by End-Use - Percentage Breakdown of Value Revenues for Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes for the Years 2014, 2024 & 2030
  • JAPAN
    • Microbial Fermentation Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Japan 16-Year Perspective for Microbial Fermentation Technology by Application - Percentage Breakdown of Value Revenues for Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for Microbial Fermentation Technology by End-Use - Percentage Breakdown of Value Revenues for Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes for the Years 2014, 2024 & 2030
  • CHINA
    • Microbial Fermentation Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 56: China Recent Past, Current & Future Analysis for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: China 16-Year Perspective for Microbial Fermentation Technology by Application - Percentage Breakdown of Value Revenues for Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 59: China Recent Past, Current & Future Analysis for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: China 16-Year Perspective for Microbial Fermentation Technology by End-Use - Percentage Breakdown of Value Revenues for Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes for the Years 2014, 2024 & 2030
  • EUROPE
    • Microbial Fermentation Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Microbial Fermentation Technology by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Microbial Fermentation Technology by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Europe 16-Year Perspective for Microbial Fermentation Technology by Geographic Region - Percentage Breakdown of Value Revenues for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Europe 16-Year Perspective for Microbial Fermentation Technology by Application - Percentage Breakdown of Value Revenues for Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Europe 16-Year Perspective for Microbial Fermentation Technology by End-Use - Percentage Breakdown of Value Revenues for Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes for the Years 2014, 2024 & 2030
  • FRANCE
    • Microbial Fermentation Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 71: France Recent Past, Current & Future Analysis for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: France Historic Review for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: France 16-Year Perspective for Microbial Fermentation Technology by Application - Percentage Breakdown of Value Revenues for Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 74: France Recent Past, Current & Future Analysis for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: France Historic Review for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: France 16-Year Perspective for Microbial Fermentation Technology by End-Use - Percentage Breakdown of Value Revenues for Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes for the Years 2014, 2024 & 2030
  • GERMANY
    • Microbial Fermentation Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 77: Germany Recent Past, Current & Future Analysis for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Germany Historic Review for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Germany 16-Year Perspective for Microbial Fermentation Technology by Application - Percentage Breakdown of Value Revenues for Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 80: Germany Recent Past, Current & Future Analysis for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Germany Historic Review for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Germany 16-Year Perspective for Microbial Fermentation Technology by End-Use - Percentage Breakdown of Value Revenues for Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 83: Italy Recent Past, Current & Future Analysis for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Italy Historic Review for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Italy 16-Year Perspective for Microbial Fermentation Technology by Application - Percentage Breakdown of Value Revenues for Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 86: Italy Recent Past, Current & Future Analysis for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Italy Historic Review for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Italy 16-Year Perspective for Microbial Fermentation Technology by End-Use - Percentage Breakdown of Value Revenues for Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Microbial Fermentation Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 89: UK Recent Past, Current & Future Analysis for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: UK Historic Review for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: UK 16-Year Perspective for Microbial Fermentation Technology by Application - Percentage Breakdown of Value Revenues for Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 92: UK Recent Past, Current & Future Analysis for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: UK Historic Review for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: UK 16-Year Perspective for Microbial Fermentation Technology by End-Use - Percentage Breakdown of Value Revenues for Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 95: Spain Recent Past, Current & Future Analysis for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Spain Historic Review for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Spain 16-Year Perspective for Microbial Fermentation Technology by Application - Percentage Breakdown of Value Revenues for Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 98: Spain Recent Past, Current & Future Analysis for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Spain Historic Review for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Spain 16-Year Perspective for Microbial Fermentation Technology by End-Use - Percentage Breakdown of Value Revenues for Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 101: Russia Recent Past, Current & Future Analysis for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Russia Historic Review for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Russia 16-Year Perspective for Microbial Fermentation Technology by Application - Percentage Breakdown of Value Revenues for Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 104: Russia Recent Past, Current & Future Analysis for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Russia Historic Review for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Russia 16-Year Perspective for Microbial Fermentation Technology by End-Use - Percentage Breakdown of Value Revenues for Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 107: Rest of Europe Recent Past, Current & Future Analysis for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Rest of Europe Historic Review for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Rest of Europe 16-Year Perspective for Microbial Fermentation Technology by Application - Percentage Breakdown of Value Revenues for Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 110: Rest of Europe Recent Past, Current & Future Analysis for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Rest of Europe Historic Review for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Rest of Europe 16-Year Perspective for Microbial Fermentation Technology by End-Use - Percentage Breakdown of Value Revenues for Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Microbial Fermentation Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for Microbial Fermentation Technology by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 114: Asia-Pacific Historic Review for Microbial Fermentation Technology by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Asia-Pacific 16-Year Perspective for Microbial Fermentation Technology by Geographic Region - Percentage Breakdown of Value Revenues for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 116: Asia-Pacific Recent Past, Current & Future Analysis for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Asia-Pacific Historic Review for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: Asia-Pacific 16-Year Perspective for Microbial Fermentation Technology by Application - Percentage Breakdown of Value Revenues for Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 119: Asia-Pacific Recent Past, Current & Future Analysis for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: Asia-Pacific Historic Review for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: Asia-Pacific 16-Year Perspective for Microbial Fermentation Technology by End-Use - Percentage Breakdown of Value Revenues for Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Microbial Fermentation Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 122: Australia Recent Past, Current & Future Analysis for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Australia Historic Review for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: Australia 16-Year Perspective for Microbial Fermentation Technology by Application - Percentage Breakdown of Value Revenues for Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 125: Australia Recent Past, Current & Future Analysis for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Australia Historic Review for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: Australia 16-Year Perspective for Microbial Fermentation Technology by End-Use - Percentage Breakdown of Value Revenues for Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes for the Years 2014, 2024 & 2030
  • INDIA
    • Microbial Fermentation Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 128: India Recent Past, Current & Future Analysis for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: India Historic Review for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: India 16-Year Perspective for Microbial Fermentation Technology by Application - Percentage Breakdown of Value Revenues for Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 131: India Recent Past, Current & Future Analysis for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: India Historic Review for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: India 16-Year Perspective for Microbial Fermentation Technology by End-Use - Percentage Breakdown of Value Revenues for Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 134: South Korea Recent Past, Current & Future Analysis for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: South Korea Historic Review for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: South Korea 16-Year Perspective for Microbial Fermentation Technology by Application - Percentage Breakdown of Value Revenues for Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 137: South Korea Recent Past, Current & Future Analysis for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: South Korea Historic Review for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: South Korea 16-Year Perspective for Microbial Fermentation Technology by End-Use - Percentage Breakdown of Value Revenues for Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 140: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Rest of Asia-Pacific Historic Review for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Rest of Asia-Pacific 16-Year Perspective for Microbial Fermentation Technology by Application - Percentage Breakdown of Value Revenues for Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 143: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Rest of Asia-Pacific Historic Review for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Rest of Asia-Pacific 16-Year Perspective for Microbial Fermentation Technology by End-Use - Percentage Breakdown of Value Revenues for Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Microbial Fermentation Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 146: Latin America Recent Past, Current & Future Analysis for Microbial Fermentation Technology by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 147: Latin America Historic Review for Microbial Fermentation Technology by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Latin America 16-Year Perspective for Microbial Fermentation Technology by Geographic Region - Percentage Breakdown of Value Revenues for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 149: Latin America Recent Past, Current & Future Analysis for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Latin America Historic Review for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Latin America 16-Year Perspective for Microbial Fermentation Technology by Application - Percentage Breakdown of Value Revenues for Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 152: Latin America Recent Past, Current & Future Analysis for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Latin America Historic Review for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Latin America 16-Year Perspective for Microbial Fermentation Technology by End-Use - Percentage Breakdown of Value Revenues for Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 155: Argentina Recent Past, Current & Future Analysis for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Argentina Historic Review for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Argentina 16-Year Perspective for Microbial Fermentation Technology by Application - Percentage Breakdown of Value Revenues for Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 158: Argentina Recent Past, Current & Future Analysis for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Argentina Historic Review for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Argentina 16-Year Perspective for Microbial Fermentation Technology by End-Use - Percentage Breakdown of Value Revenues for Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 161: Brazil Recent Past, Current & Future Analysis for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Brazil Historic Review for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Brazil 16-Year Perspective for Microbial Fermentation Technology by Application - Percentage Breakdown of Value Revenues for Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 164: Brazil Recent Past, Current & Future Analysis for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Brazil Historic Review for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Brazil 16-Year Perspective for Microbial Fermentation Technology by End-Use - Percentage Breakdown of Value Revenues for Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 167: Mexico Recent Past, Current & Future Analysis for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Mexico Historic Review for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Mexico 16-Year Perspective for Microbial Fermentation Technology by Application - Percentage Breakdown of Value Revenues for Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 170: Mexico Recent Past, Current & Future Analysis for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Mexico Historic Review for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Mexico 16-Year Perspective for Microbial Fermentation Technology by End-Use - Percentage Breakdown of Value Revenues for Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 173: Rest of Latin America Recent Past, Current & Future Analysis for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Rest of Latin America Historic Review for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: Rest of Latin America 16-Year Perspective for Microbial Fermentation Technology by Application - Percentage Breakdown of Value Revenues for Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 176: Rest of Latin America Recent Past, Current & Future Analysis for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Rest of Latin America Historic Review for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: Rest of Latin America 16-Year Perspective for Microbial Fermentation Technology by End-Use - Percentage Breakdown of Value Revenues for Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Microbial Fermentation Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 179: Middle East Recent Past, Current & Future Analysis for Microbial Fermentation Technology by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 180: Middle East Historic Review for Microbial Fermentation Technology by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: Middle East 16-Year Perspective for Microbial Fermentation Technology by Geographic Region - Percentage Breakdown of Value Revenues for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 182: Middle East Recent Past, Current & Future Analysis for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Middle East Historic Review for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Middle East 16-Year Perspective for Microbial Fermentation Technology by Application - Percentage Breakdown of Value Revenues for Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 185: Middle East Recent Past, Current & Future Analysis for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Middle East Historic Review for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Middle East 16-Year Perspective for Microbial Fermentation Technology by End-Use - Percentage Breakdown of Value Revenues for Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 188: Iran Recent Past, Current & Future Analysis for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Iran Historic Review for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Iran 16-Year Perspective for Microbial Fermentation Technology by Application - Percentage Breakdown of Value Revenues for Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 191: Iran Recent Past, Current & Future Analysis for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Iran Historic Review for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: Iran 16-Year Perspective for Microbial Fermentation Technology by End-Use - Percentage Breakdown of Value Revenues for Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 194: Israel Recent Past, Current & Future Analysis for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Israel Historic Review for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: Israel 16-Year Perspective for Microbial Fermentation Technology by Application - Percentage Breakdown of Value Revenues for Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 197: Israel Recent Past, Current & Future Analysis for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Israel Historic Review for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: Israel 16-Year Perspective for Microbial Fermentation Technology by End-Use - Percentage Breakdown of Value Revenues for Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 200: Saudi Arabia Recent Past, Current & Future Analysis for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Saudi Arabia Historic Review for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: Saudi Arabia 16-Year Perspective for Microbial Fermentation Technology by Application - Percentage Breakdown of Value Revenues for Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 203: Saudi Arabia Recent Past, Current & Future Analysis for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Saudi Arabia Historic Review for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: Saudi Arabia 16-Year Perspective for Microbial Fermentation Technology by End-Use - Percentage Breakdown of Value Revenues for Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 206: UAE Recent Past, Current & Future Analysis for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: UAE Historic Review for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: UAE 16-Year Perspective for Microbial Fermentation Technology by Application - Percentage Breakdown of Value Revenues for Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 209: UAE Recent Past, Current & Future Analysis for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 210: UAE Historic Review for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 211: UAE 16-Year Perspective for Microbial Fermentation Technology by End-Use - Percentage Breakdown of Value Revenues for Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 212: Rest of Middle East Recent Past, Current & Future Analysis for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Rest of Middle East Historic Review for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 214: Rest of Middle East 16-Year Perspective for Microbial Fermentation Technology by Application - Percentage Breakdown of Value Revenues for Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 215: Rest of Middle East Recent Past, Current & Future Analysis for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 216: Rest of Middle East Historic Review for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 217: Rest of Middle East 16-Year Perspective for Microbial Fermentation Technology by End-Use - Percentage Breakdown of Value Revenues for Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes for the Years 2014, 2024 & 2030
  • AFRICA
    • Microbial Fermentation Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 218: Africa Recent Past, Current & Future Analysis for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 219: Africa Historic Review for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 220: Africa 16-Year Perspective for Microbial Fermentation Technology by Application - Percentage Breakdown of Value Revenues for Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 221: Africa Recent Past, Current & Future Analysis for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 222: Africa Historic Review for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 223: Africa 16-Year Perspective for Microbial Fermentation Technology by End-Use - Percentage Breakdown of Value Revenues for Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes for the Years 2014, 2024 & 2030

IV. COMPETITION